Teva Surprises With Better-than-expected First Quarter

Trouble drugmaker offers rosier outlook for rest of year, despite delay in approval for key migraine treatment

Yoram Gabison
Yoram Gabison
A Teva Pharmaceutical Industries building in Jerusalem, December 14, 2017.
A Teva Pharmaceutical Industries building in Jerusalem, December 14, 2017.Credit: \ Ammar Awad/ REUTERS

Comments